RT @_ShankarSiva: @DrAndrewLoblaw @dr_jonathant @PCaParker @DocJarad @sandraturner49 I agree, i think SABR for prostate oligomets is still…
@DrAndrewLoblaw @dr_jonathant @PCaParker @DocJarad @sandraturner49 I agree, i think SABR for prostate oligomets is still investigational, really only for carefully selected patients with PET detected disease. Great recent phII RCT by @piet_ost here https:
RT @Rad_Nation: STOMP trial doesn't apply to this M1 group but for those who already failed primary therapy https://t.co/BYz6GBGJWp #radonc
STOMP trial doesn't apply to this M1 group but for those who already failed primary therapy https://t.co/BYz6GBGJWp #radonc
Surveillance or metastasis-directed Therapy for OligoMetastatic #pcsm recurrence (STOMP): study prot... https://t.co/jePNikF3ja #SBRT
STOMP, yet another brilliant acronym for a study that involves stereotactic radiotherapy. Even @_ShankarSiva would be proud. #radonc https://t.co/ZrVXODB4St
RT @hagsie: #ANZUP16 @piet_ost stay tuned for the results of ##STOMP #RCT in October 2016 here's the protocol in the meantime https://t.co/…
#ANZUP16 @piet_ost stay tuned for the results of ##STOMP #RCT in October 2016 here's the protocol in the meantime https://t.co/6VRGucTNKN
@Dr_Shankar_Siva @declangmurphy evidence is being generated for both surgery and SABR https://t.co/wAKBatjyFj #radonc
Surveillance or metastasis-directed therapy for OligoMetastatic #Prostatecancer recurrence (STOMP):study protocol http://t.co/YtFF0s67m5